{"title":"Adamantane Appended 1,2,3-Triazole Hybrids: Synthesis and α-Glucosidase Inhibition Studies Through Experimental and In Silico Approach.","authors":"Aman Ragshaniya, Subhadip Maity, Lokesh Kumar, Vivek Asati, Poojita Poojita, Avijit Kumar Paul, Jayant Sindhu, Kashmiri Lal","doi":"10.1002/cmdc.202500263","DOIUrl":null,"url":null,"abstract":"<p><p>In search of potent inhibitors of α-glucosidase, we have synthesized amide coupled adamantane derived 1,2,3-triazoles (4a-4f, 6a-6f, and 8a-8f) using Click reaction. After establishing their structure using spectral studies, all the molecular hybrids were assayed for α-glucosidase inhibition assay. Compounds 6c (IC50 = 8.30 ± 0.33 μM) and 6b (IC50 = 14.0 ± 0.16 μM) demonstrated promising inhibition of α-glucosidase in comparison to reference used (Acarbose, IC50 = 13.50 ± 0.32 μM). The role of various covalent linkers between triazole and phenyl ring has been established using structure activity relationship (SAR). The most probable mode of inhibition was studied by docking the most active compound 6c and Acarbose within the protein target (PDB ID: 3L4U). Further, 100 ns dynamics simulations were conducted to gain a detailed understanding of the complex stability. Binding energy for both the simulated complexes was calculated using MMGBSA and MMPBSA analysis, where compound 6c and Acarbose demonstrates a ΔGbind of -15.74 kcal/mol, and -46.37 kcal/mol. All compounds fit in the Lipinski rules of five, when ADME studies was carried out. This study paves the way for developing small molecule based α-glucosidase inhibitors as potential lead molecules using these frameworks.</p>","PeriodicalId":147,"journal":{"name":"ChemMedChem","volume":" ","pages":"e202500263"},"PeriodicalIF":3.6000,"publicationDate":"2025-07-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ChemMedChem","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/cmdc.202500263","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"CHEMISTRY, MEDICINAL","Score":null,"Total":0}
引用次数: 0
Abstract
In search of potent inhibitors of α-glucosidase, we have synthesized amide coupled adamantane derived 1,2,3-triazoles (4a-4f, 6a-6f, and 8a-8f) using Click reaction. After establishing their structure using spectral studies, all the molecular hybrids were assayed for α-glucosidase inhibition assay. Compounds 6c (IC50 = 8.30 ± 0.33 μM) and 6b (IC50 = 14.0 ± 0.16 μM) demonstrated promising inhibition of α-glucosidase in comparison to reference used (Acarbose, IC50 = 13.50 ± 0.32 μM). The role of various covalent linkers between triazole and phenyl ring has been established using structure activity relationship (SAR). The most probable mode of inhibition was studied by docking the most active compound 6c and Acarbose within the protein target (PDB ID: 3L4U). Further, 100 ns dynamics simulations were conducted to gain a detailed understanding of the complex stability. Binding energy for both the simulated complexes was calculated using MMGBSA and MMPBSA analysis, where compound 6c and Acarbose demonstrates a ΔGbind of -15.74 kcal/mol, and -46.37 kcal/mol. All compounds fit in the Lipinski rules of five, when ADME studies was carried out. This study paves the way for developing small molecule based α-glucosidase inhibitors as potential lead molecules using these frameworks.
期刊介绍:
Quality research. Outstanding publications. With an impact factor of 3.124 (2019), ChemMedChem is a top journal for research at the interface of chemistry, biology and medicine. It is published on behalf of Chemistry Europe, an association of 16 European chemical societies.
ChemMedChem publishes primary as well as critical secondary and tertiary information from authors across and for the world. Its mission is to integrate the wide and flourishing field of medicinal and pharmaceutical sciences, ranging from drug design and discovery to drug development and delivery, from molecular modeling to combinatorial chemistry, from target validation to lead generation and ADMET studies. ChemMedChem typically covers topics on small molecules, therapeutic macromolecules, peptides, peptidomimetics, and aptamers, protein-drug conjugates, nucleic acid therapies, and beginning 2017, nanomedicine, particularly 1) targeted nanodelivery, 2) theranostic nanoparticles, and 3) nanodrugs.
Contents
ChemMedChem publishes an attractive mixture of:
Full Papers and Communications
Reviews and Minireviews
Patent Reviews
Highlights and Concepts
Book and Multimedia Reviews.